Please login to the form below

Not currently logged in
Email:
Password:

safinamide

This page shows the latest safinamide news and features for those working in and with pharma, biotech and healthcare.

FDA approves Newron's Parkinson's disease drug Xadago

FDA approves Newron's Parkinson's disease drug Xadago

Newron Pharmaceuticals’ Xadago (safinamide) was approved as an add-on treatment for patients already on levodopa/carbidopa and who experience ‘off’ episodes when those medications don’t work well.

Latest news

  • Newron back on track for Xadago approval in US Newron back on track for Xadago approval in US

    The Italian pharma company's partner Zambon is already rolling Xadago (safinamide) out in Europe following its EMA approval last year, and has just launched in Norway taking the tally of ... We assume the safinamide label could be expanded to include

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    neprilysin inhibitor. Novartis. USA. safinamide. Xadago. Parkinson's disease. MAO-B inhibitor. Newron Pharma.

  • Chasing the cure for Parkinson's disease Chasing the cure for Parkinson's disease

    Currently available therapies of this class include selegiline and rasagiline. Safinamide (Newron, Zambon and Meiji Seika Pharma) is a selective and reversible MAO B inhibitor in the absence of MAO-A

  • Oncology bias in pharma deals

    Merck Serono's decision to return the rights to Safinamide (an alpha aminoaminde in phase III, as an add-on therapy to dopamine agonists or levodopa for dyskinesia in Parkinson's ... Termination of acquisition. Safinamide (alpha aminoamide) adjunct

  • Next generation

    Safinamide (Merck Serono) is an MAOB inhibitor currently in phase III trials as an adjunctive therapy for the treatment of PD. ... However, safinamide also acts as a glutamate release inhibitor, as well as a sodium and calcium channel blocker.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics